Elranatamab vs Daratumumab with RVd Lite for New Myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial compares two treatments for newly diagnosed multiple myeloma patients who are not eligible for or have delayed stem cell transplant. One group gets elranatamab plus a light version of RVd (lenalidomide, bortezomib, dexamethasone), and the other gets daratumumab plus the same light RVd. The goal is to find which combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have newly diagnosed multiple myeloma with signs of organ damage or high-risk markers.
- You have measurable disease (e.g., a certain level of M-protein in blood or urine).
- Your doctor says you are not eligible for or have decided to delay a stem cell transplant.
- You have good enough organ function (kidneys, liver, blood counts) to participate.
- You are willing to use effective birth control if needed and to have follow-up tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) mixed with myeloma cells, given together with a drug called elranatamab. It is for people with multiple myeloma that has not responded to at least three prior treatments.
This Phase 3 study compares a three-drug combination (elranatamab, daratumumab, and lenalidomide) versus a standard three-drug treatment (daratumumab, bortezomib, lenalidomide, plus dexamethasone). It aims to see which plan works better for people newly diagnosed with multiple myeloma who cannot get a stem cell transplant.
This trial studies elranatamab (alone and combined with daratumumab) in people with multiple myeloma who have already received other treatments, including lenalidomide. It aims to see how well these medicines control the cancer and what side effects people experience.
This trial tests whether a new drug called elranatamab combined with lenalidomide works better than the standard daratumumab/lenalidomide combination as maintenance therapy after a stem cell transplant for newly diagnosed myeloma.
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.